As activity intensifies in neurological disorders such as ALS and Parkinson's disease, this article presents an overview of 20 Japan-based drug-discovery companies and the full schedule of related catalysts. It lists current developments and potential future catalysts.
The catalyst was 6 March 2026, when Amschepri, an allogeneic iPS cell-derived neural progenitor cell product developed by Sumitomo Pharma and RACTHERA, received conditional and time-limited approval in Japan. This marked the world's first iPS cell-derived regenerative and cellular medicine product. The product is based on data from Kyoto University, and research findings published in Nature have been reported.
That same month, SanBio indicated that it expected a regenerative medical device for motor paralysis to be listed for reimbursement and launched in May 2026, with initial shipments targeted for the second half of 2027. In addition, on 16 September 2026, Eisai's anti-amyloid-beta antibody product was approved in Japan, raising the possibility that administration in the home could become a practical option.
The first reason cited is progress in diagnosis. It is explained that a blood test for Alzheimer's disease has received FDA approval and could expand the eligible patient population as an alternative to PET scans and cerebrospinal fluid testing. The second is that Japan-based basic research is beginning to reach the clinic, with Japanese laboratories producing treatment candidates for ALS and multiple system atrophy. The third is the combination of large markets, including dementia and Parkinson's disease, with rare diseases where drug prices are expected to rise and demographic trends.
The article aims to select 20 Japanese stocks from across the value chain, from drug-discovery ventures and major pharmaceutical companies to diagnostics, medical devices and home healthcare, and to present a diversified group by market capitalization and industry together with a list of future catalysts.